Home » Topics » Diagnostics, BioWorld Science

Diagnostics, BioWorld Science
RSS

Nycomed discontinues development of MRI contrast agent

Nov. 8, 1996

Research Triangle Institute describes high-affinity and selective ligand for dopamine transporter

Nov. 8, 1996

MAb for diagnosis of malignant tumors

Nov. 8, 1996

Eiken contrast agents in development

Nov. 1, 1996

Diatide's P483H Techtide receives patent protection in U.S.

Nov. 1, 1996

Third-generation ultrasound contrast agent from Sonus

Nov. 1, 1996

Schering AG describes radiographic contrast agent

Nov. 1, 1996

MRI contrast agents from Nycomed Salutar

Nov. 1, 1996

Cell motility factor with potential in cancer diagnostics and therapeutics available for licensing

Oct. 25, 1996

Licensees sought for antibodies specific for P31 antigen for use in lung cancer detection

Oct. 25, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...